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Background: Cells, growth factors (GFs), and scaffold are three essential factors for 
tissue engineering. Our previous studies suggested that multiple applications of human 
amnion growth factors (AGF) into osseous defects could “mimic in-utero” growth. 
However, micro-gaps still exist between the scaffold and recipient tissue. We 
hypothesized that hyaluronic acid (HA) could act an accessory scaffold and gradually 
release active components of AGF and improve bone healing.  
Materials and Methods: Calvaria from 50 7–9-day old CD1 neonatal mice were 
harvested, and a 2 mm defect punch made in each one. A type I collagen membrane with 
AGF alone or with HA at different concentrations applied over the defect. The culture 
medium was changed every 2-3 days and collected for alkaline phosphatase (ALP) and 
protein analysis.  
 
 vi 
Results: A single dose of AGF combined with 0.125% HA increased cellular infiltration 
into the defect area more than AGF with no HA or a lower concentration of HA 
(0.0625%). A single dose of AGF with HA can improve bone healing. 
Conclusion: A single dose of AGF with HA as an extra scaffold and a carrier can 
achieve bone formation like multiple dosages of AGF and reduce the number of clinical 
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Section One: Tissue Engineering 
The Tissue Engineering Society (TES) was created in 1994 in Boston, Massachusetts by: 
Drs. Charles A. and Joseph P. Vacanti [1]. Tissue engineering is a discipline dedicated to 
tissue regeneration using engineering with biological sciences concepts. One of the most 
important tissue engineering was performed by Dr. Charles Vacanti at the University of 
Massachusetts Medical Center, in which he engineered cartilage in the shape of a human 
ear onto the spine of a mouse [1]. Most tissue engineering research has been based on the 
principles used for the “Vacanti Mouse”, that new tissue can be regenerated from cells 
placed with supporting scaffolds [1] [2].  
 
Successful tissue engineering requires three components: (i) direct injection of cells into 
the tissue or the circulation (stem cells), (ii) implantation of biochemical factors such as 
growth factors (GF), and (iii) a scaffold that will stimulate cell migration, growth, and 
differentiation (figure 1). In bone these allow stem cell and osteoblast differentiation, 






Figure 1: Tissue Engineering Triad.  This diagram demonstrates the three main 
components of the tissue engineering triad which include cells, GFs, and scaffolds. 
 
The purpose of tissue engineering is to restore, preserve, and improve damaged tissues 
[3]. Natural scaffolds derived from the extracellular matrix (ECM) include proteins such 
as collagen and fibrin and polysaccharide-based glycosaminoglycans and hyaluronic acid 
(HA). The chemical factors include bone morphogenic proteins (BMPs), basic fibroblast 
growth factors, vascular endothelial growth factors, and transforming growth factors. 
These growth factors are soluble in nature and can be incorporated into a scaffold.  
 
There are two methods to successfully engineer tissues. The first method uses an in-vitro 





The second method uses growth factors for cell recruitment and differentiation. GF 
delivery systems are defined by their matrix structure such as particulates, scaffolds or 
hydrogels [3] [5]. 
 
The goal is to choose a combination of cell types, scaffolds, and growth factors [4] that 
will achieve bone regeneration with integration into the surrounding tissues and 
replacement of the scaffold with new bone.  
 
The scaffold is a three-dimensional structure and GF delivery system that will support 
cell growth and cell differentiation [5]. One of the challenges in tissue engineering is to 
develop a successful scaffold that has the necessary properties for bone regeneration. 
These properties include: 
1. Osteoconduction:  
2. Osteoinduction 
3.  Biocompatibility 
4. Biodegradability 
5. Vascularization 
6.  Progenitor cell retention 
 
 





The osteoconduction property of the scaffold provides a carrier for the progenitor cells 
and creates a “microenvironment” in which the progenitor cells can differentiate and 
produce viable bone [3] [4]. During bone fracture healing, the cartilaginous callus goes 
through various stages and is eventually replaced by new bone. The scaffold must be able 
to emulate this characteristic. Scaffolds must also bridge the gap between the defect and 
the surrounding bone. Interactions of a scaffold and progenitor cells are critical in bone 
regeneration and should mimic a natural cell receptor and ECM interaction.  
 
Osteoinduction is necessary for regenerative healing that requires mesenchymal stem 
cells from the bone marrow. A scaffold that can induce osteoinduction will allow 
progenitor cell adhesion and sustained delivery of growth factors [4] [5]. A scaffold 
should also be biodegradable and provide only temporary support for bone formation.  
 
Section Two: Collagen Membrane 
Collagen is the most abundant protein found in animals [6] and is the main structural 
protein of most hard and soft tissues in the human body. It maintains the biological and 
structural integrity of the ECM. Collagen scaffolds are used in tissue engineering due to 
their low immunogenicity, permeability, biocompatibility, and biodegradability. 
However, there are limitations to the use of collagen as scaffolds in certain tissues as they 
lack mechanical strength and structural stability upon hydration. To overcome this 
shortcoming collagen can be cross-linked by chemical methods or modified by 







Collagen can be classified based on its compositional and structural characteristics into 
the following classes: “(i) collagen with classically compact banded structures, including 
type I, II, and III collagen; (ii) collagen with open fiber structures such as type IV 
basement membrane collagen; (iii) type V collagen and molecules containing the E and F 
chains; (iv) collagen with a discontinuous triple helix” [7]. 
 
Structure: 
Collagen is a trimeric molecule consisting of three polypeptide α chains in a triple helix, 
creating either homotrimers or heterotrimer. The triple helix encompasses Gly-X-Y 
repeats, in which the X can be proline and the Y can be 4-hydroxyproline. Type I 
collagen, the most abundant protein in vertebrates, is a heterotrimer consisting of two α1 
and one α2 chain with a 50 nm diameter [6]. It makes up for 90% of the bone organic 
matrix and can be a structural scaffold for skin and connective tissues.  
 
Biological characteristics: 
Collagen is a poor immunogen. The main antigenic determinant is in the non-helical 
telopeptide region and secondary one is in the helical region. Removal of the non-helical 
regions of collagen suppresses its antigenicity. Cross-linking can also reduce the 






Although collagen is a stable structure due to its crosslinks, it can be broken down by 
enzymatic catabolism. Collagenase binds to the exterior portion of the triple helix and 
degrades the collagen fibrils. The resulting small peptides then can be degraded by other 
proteinases and gelatinases [7]. Collagen degradation is affected by the number of cross-
links involved; more intensely cross-linked fibers are less subject to breakdown. 
 
Historical Background: 
In 1986, a model of vascular tissue was created using “smooth muscle cell-populated 
collagen” for the tunica media layer of blood vessels [8]. This model lacked mechanical 
strength. In 1993, another model was based on the previous model but used cells from a 
different source [9]. This model also failed.  
One of the few scaffolds used clinically is a collagen-glycosaminoglycan mesh. This has 
been used in diabetes associated foot ulcers as an artificial scaffold to stimulate skin cell 
growth and differentiation and tissue bridging [10].  
 
Section Three: Growth Factors  
Growth factors (GF) are soluble proteins secreted by cells that regulate cellular processes 
and aid in tissue regeneration [11]. These include bone morphogenic proteins (BMP), 
transforming growth factor-beta (TGF-b), fibroblast growth factor (FGF), platelet-derived 
growth factor (PDGF), and insulin-like growth factor (IGF) [12]. These proteins improve 





transmembrane receptors on the target cells. GFs can also be directly applied into the 
defect site.   
 
Mode of Action: 
Growth factors (GF) may serve in one of three capacities: (i) autocrine, (ii) paracrine, and 
(iii) endocrine. As an autocrine factor, GFs influence the cells that produce them. 
Paracrine factors affect the cells in the immediate vicinity. Endocrine factors are secreted 
into the circulation and can influence cells in different locations [13].  
 
When a GF reaches the cell, it binds to a target cell receptor activating an intracellular 
signal transduction system to produce a biological response. This occurs as a ligand-
receptor interaction [13] [14]. These interactions can be either simple or complex 
depending on specific growth factors (ligands). For instance, a specific growth factor can 
bind to a single receptor. In other instances, one or more ligands can bind to one or more 
receptors [13] [12]. Receptors can have both an extracellular domain and an intracellular 
domain. The extracellular domain binds to the ligand i.e., receptors; and the intracellular 
domain activates a signal transduction. After the ligand-receptor interaction, the receptor 
is activated by a change in conformation. The signal transduction activates a transcription 
factor, an intracellular protein. This transcription factor then enters the nucleus and binds 
to the nuclear deoxyribonucleic acid (DNA), thereby inducing an expression of a new 







Figure 2: GFs influence on cells. This figure demonstrates the influence of the GFs on 
an affected cell. The ligand binds to the extracellular domain of the receptor and the 
intracellular domain of the receptor activates a signal transduction. The signal 
transduction system then activates the transcription factor that enters the nucleus and 
binds to DNA leading to a gene expression.  
 
The effect of GFs on healing depends on its chemical structure, concentration, and the 
extracellular matrix of the area where the GFs are applied [11]. 
 
Limitations: 
The use of growth factors has major limitations in clinical applications. One limitation is 





enzymes. Consequently, several clinical trials involving the use of GFs have led to 
inadequate tissue regeneration. One reason for these failures was the mode of delivery. In 
these trials, GFs were either injected directly into the body, topically applied, or even 
sprayed onto the defect. In one clinical trial, fibroblast growth factor 2 (FGF-2) was 
injected into periodontal tissue during surgery, vascular endothelial growth factor 1 
(VEGF-1) was placed directly onto diabetic foot ulcers, and acidic FGF was sprayed onto 
burn wounds [15].  The GFs administered in this manner led to serious side effects 
including tumor formation. It can also be noted that there was not enough time for the 
target tissues to utilize the GFs due to rapid degradation. The bioavailability was also 
limited because of the loss of GFs due to diffusion leading to larger and repeated amounts 
of GFs applied. This was seen in previous studies with AGF applications onto critical 
defects of calvaria. These limitations lead us to believe that a delivery system for GFs is 
vital for successful tissue regeneration.  
 
A sustained release GF delivery system can achieve localized, high concentrations of GFs 
that are necessary for tissue regeneration especially when the application is restricted to 
the local/defect area. A scaffold provides not only structural support, but also facilitates 
tissue regeneration by ensuring that GFs remain in the defect site so that host cells can 





In critical-sized bone defects, topical application of GFs is ineffective as there is no 
system to maintain continuous GF release. Biomaterial carriers such as collagen, 
hydrogels, and nanoparticles can lead to continuous release of GFs while bridging the 
“micro-gaps” between the defect and the surrounding tissues [15].  
 
In conclusion, GFs need a biological carrier and scaffold that can enhance GFs 
effectiveness and improve tissue repair and cellular regeneration by controlling GFs 
release. The scaffolds used in this experiment are type I collagen membrane and HA. 
 
AminoSpark: 
AminoSpark is a liquid form of amnion growth factors by Salvin Dental Specialties. It is 
composed of “chorion-free morscelized human amnion tissue” as stated on the Salvin 
website. It was created to assist in tissue restoration and wound healing. AminoSpark 
contains growth factors such as: bone morphogenetic protein 4 (BMP-4), bone 
morphogenetic protein 5 (BMP-5), bone morphogenetic protein 7 (BMP-7), platelet 
derived growth factor (PDGF-AA), platelet derived growth factor (PDGF-BB), VEGA, 
transforming growth factor-B1 (TGI-B1), osteoprotegerin (OPG), stem cell factor (SCF), 
epidermal growth factor (EGF), and interleukin 6 (IL-6). 
 
The growth factor TGF-ß superfamily includes: TGF-B, activins, and BMPs [16] . This 
superfamily members bind to type I and/or II receptors of the serine/threonine kinase type 





development by stimulating or inhibiting cellular proliferation, prompting apoptosis of 
cells, and stimulating neuronal cell survival [16]. Marshall Urist coined the term BMP in 
1970 after demonstrating that these proteins play a role in osteogenesis and bone 
formation in 1970. Since then, 20 different BMPs have been discovered and categorized 
based on the amino acid sequence [17].  
 
BMP-4: This is a crucial molecule with many different functions. BMP-4 is present in the 
human body at various stages such as tooth development, bone induction, and fracture 
repair [18]. BMP-4 is increased in patients with fibrodysplasia ossificans progressiva 
[18]. Tissues that express BMP-4 include prostate, skeletal muscle, bone marrow, 
thymus, spleen, and spinal cord [17]. BMP-4 can also induce cartilage formation and 
promote new bone formation.  
 
BMP-5: BMP-5 is also known as MGC34244 [17]. It functions in limb development; 
cartilage and bone morphogenesis; and linking soft tissues [17]. It is expressed in the 
nervous system during development and through adulthood [19].  
 
BMP-7: BMP-7, also known as OP-1, induces cartilage hypertrophy and is present in the 
early development of the nervous system [17]. It is an effective anti-inflammatory GF. 
BMP-7 acts by targeting cells and binding to specific membrane-bound receptor BMPR 
thereby transducing signals against SMADs and mitogen activated protein kinase 





cells bordering bone to differentiate into chondrocytes and osteoclasts at fracture sites. 
New bone formation is followed by calcium deposition thereby repairing bone fractures 
[17].  
 
PDGF regulates cell growth and proliferation. It plays an important role in the formation 
of blood vessels through proliferation of mesenchymal cells. 
 
IL-6: IL-6 is a multifunctional cytokine that plays a role in host defense [20]. It is 
important in induction of the acute phase response [20]. IL-6 synthesis and release is 
dramatically increased in diseases such as multiple myeloma, rheumatoid arthritis, 
Castleman's disease, psoriasis, and post-menopausal osteoporosis [20].  
 
EGF: EGF and EGF receptors play an important role in wound healing by epidermal and 
dermal regeneration [21]. It stimulates the keratinocytes, endothelial cells, and fibroblasts 
[21]. EGF binds to the EGF receptor known as EGFR or ErbB that induces the 
intracellular signaling [22].  
 
Section Four: Amniotic Growth Factors  
Amniotic fluid (AF) is the protective liquid for a developing embryo. The amniotic 
membrane (AM) is the inner layer of a fetal membrane consisting of three layers (9):  
i. Monolayer of epithelial cells,  





iii. Outer mesenchymal cell layer. 
 
The human amniotic fluid (HAF) is obtained by amniocentesis between the 15th and 19th 
week of gestation. While the major component of HAF is water, the excess AF from the 
procedure can be a source of AF-derived stem cells.  HA is also found in HAF suggesting 
that AF has multiple cell types derived from the embryonic tissue that may participate in 
bone healing [23].  
 
The amniotic membrane is usually obtained during a caesarean section at the term of a 
pregnancy. AM has been used in many clinical treatments to stimulate wound healing in 
burns. AM promotes epithelium formation and can aid in protection from infection [23] 
[24].  
 
Scar formation is one the adverse effects of any surgery. Although there is no treatment 
that can prevent scarring altogether, there are ways to minimize it. In comparison to adult 
wound healing, early fetal scarring heals rapidly with an absence of scar formation. Fetal 
extracellular matrix is composed of collagen (especially type III), HA, proteoglycans, 
glycosaminoglycan, and adhesion proteins- all of which undergo modifications prior to 
reaching the adult phenotype [25]. This ECM has an important role in cell adhesion, 
differentiation, and proliferation; therefore, it plays an essential role in scarless healing 







Section Five: Hyaluronic Acid 
Hyaluronic acid (HA) was discovered from the cows’ vitreous humor by Karl Meyer and 
John Palmer in 1935 [27]. The name was derived from “hyalos” which means glass in 
Greek and uronic acid [28]. It is a high molecular weight, non-sulphated 
glycosaminoglycan (GAG) and is the only GAG not modified by the Golgi apparatus 
[29] [28].  It is a linear polysaccharide composed of repeating disaccharides of D-
glucuronic acid and N-acetyl-D-glucosamine (Figure 3). It is distributed throughout the 
connective tissue, neural tissues, epithelial tissues, and body fluids and can stimulate 
mesenchymal cell differentiation thereby promoting bone formation [30].  
 
HA received attention in the 1970s and 80s when it was developed as a product and 
approved for ophthalmic surgery. Later, it became a medication for eye surgeries by 
many corporations. Stabilization of the HA chains with agents such as NASHA (non-
animal stabilized hyaluronic acid) was used to treat diseases. Damage to the epithelial 
tissues of the corneal membrane during lens surgeries in the 1970s would lead to swelling 
and therefore HA would be used to as a viscous barrier to avoid the scraping of the 








HA is present in animal tissues and surrounds chondrocytes. Water adsorption due to HA 
leads to better flexibility in synovial joints because of the binding of HA and Hyaluronan 
and Proteoglycan Link Protein 1 (HAPLN1) leading aggrecan monomers to form larger 
aggregates. Fibroblasts are embedded within the muscular connective tissues because of 
this interaction [32]. Through cell surface receptor interactions like CD44 and RHAMM, 
HA provides tissue with better fluid mechanics, cell movement and cell proliferation. 
CD44 is a type I transmembrane glycoprotein that provides cell adhesion and therefore 
the interaction of HA with CD44 promotes cell growth. 
 
Biosynthesis: 
The synthesis of HA does not require a core protein and is synthesized by a cellular 
membrane-bound enzyme, HA synthase (HAS) on the inner surface of the membrane and 
it is extruded through “pore-like structures” [30] into the ECM.  
 
HA-Receptor Interactions and Degradation: 
HA is also an important component of skin repair. For instance, skin exposed to ultra-
violet rays can cause reddening and sunburn. This causes the dermal cells to halt HA 
production and increases degradation of HA leading to accumulation of degradation 






There are 3 main groups of cell receptors that interact with HA: CD44, RHAMM and 
intracellular adhesion molecule-1 (ICAM-1). CD44 and ICAM-1 are known as cell 
adhesion molecules. CD44 aids HA in binding in the following aspects: “cell 
aggregation, proliferation, migration, and activation, along with cell-cell and cell-
substrate adhesion” [33].  
 
HA can be degraded by hyaluronidases which hydrolyze the “hexosaminidic β (1-4) 
linkages between N-acetyl-D-glycosamine and D-glucuronic acid residues” [34]. Human 
beings have a minimum of seven kinds of hyaluronidase-like enzymes that may be tumor 
suppressors. HA degradation products, Oligosaccharide, and low molecular weighted HA 
display proangiogenic properties. There are several conditions that can cause HA’s 
primary structure to be degraded including pH, temperature, thermal, mechanical, free 
radical, ultrasonic, and enzymatic stresses [29]. The half-life of HA will vary depending 
on its location. For instance, the half-life of HA in blood can range from 3 to 5 minutes; 




Even though the HA structure is a simple polysaccharide, it has an array of biological 
functions including lubrication, wound healing, and serving as a “framework through 
which cells migrate” [30] [35]. HA synthesis increases during tissue injury and wound 






Higher weight HA occurs in intact tissues and is antiangiogenic and immunosuppressive. 
Smaller weight HAs are involved in inflammation and angiogenesis. HA has the 
capability of retaining large volumes of water leading to high viscosity even at lower 
concentrations [35].  
 
Historical Background: 
HA has been used in treatments for osteoarthritis of the knee and temporomandibular 
degenerative arthritis [36]. In recent studies, HA has been used in tissue engineering. For 
example, in dentistry, HA has been used in treatments of periodontal diseases because of 
its “anti-inflammatory, antioxidant, and antibacterial” [37] properties. It can also be used 
to maintain space in periodontitis because of its high viscoelasticity properties.  
 
In 2011, a clinical study used a scaffold with chitosan and HA for tissue regeneration in 
cartilage. They concluded that using HA enhanced cartilage formation and improved 
production of ECM [38]. In an animal study in 1995, in bone grafts HA was shown to 
have osteoinductive properties that accelerated bone formation [39]. Another animal 
study supported this result [35]. In mini pigs, coating the surfaces of the dental titanium 
implants with HA led to an increase in bone formation [35].  
 
In a study by Fujioka-Kobayashi et al., HA was successfully used with recombinant 





period of 10 days [40]. Thus, HA is a potential carrier for GFs. Several reports have also 
suggested the use of HA as a carrier and to control GFs release. Iio et al., used platelet-
rich plasma (PRP) and HA to treat osteoarthritis. The HA mixture with PRP controlled 
growth factor release, which was much higher on day 5. They concluded that HA 
combined with PRP was more effective in treatment of osteoarthritis than PRP alone 
[41].  
 
HA application in dentistry: 
HA products have recently been used in clinical dentistry. In a study with treatment of 
gingivitis, 0.2% HA based gel was used [28]. HA has anti-inflammation and anti-
edematous making it a useful therapy for plaque-induced gingivitis [28]. In gingival 
therapy, topical treatments with HA were applied from one to four weeks and from twice 
to five times daily [42]. The gingival index, papillary bleeding index, and gingival 











We hypothesized that HA would gradually release the active components of AGF, acting 
as an accessory scaffold to cover the micro-gaps and enhance cellular migration causing 




The aims of this study are to determine: 
1. the optimal ratio of AGF and HA as a carrier to release growth factors gradually 
into the defect area and increase bone formation. 
2. the mechanism by which HAF can mimic “in-utero” growth conditions and 





MATERIAL AND METHODS  
Outline: 
This study was approved by the Boston University Medical Center Institutional Animal 
Care and Use Committee (BUMC IACUC) for all animal procedures in this study 
(protocol AN-14946,15682). The animal model chosen for this experiment were 7–9-day 




Calvaria from 50, 7–9-day, neonatal CD-1 mice (Charles River Laboratories, MA) were 
dissected under sterile conditions were cut and washed briefly in culture medium. The 
bone organ culture medium consisted of Dulbecco’s modified Eagle medium (DMEM) 
supplemented with bovine serum albumin (BSA) and 1% penicillin-streptomycin solution 
(Sigma Alrrich, Co, St. Louis, MO, USA).  
 
Calvaria Harvest: 
The animal model chosen for both, experiment I and experiment II, are 50 7–9-day old 
CD1 neonatal mice. The calvaria of these mice were dissected and harvested under sterile 
conditions. The calvaria was cultured with bone forming media on a titanium mesh. Each 
calvaria was cut into two even halves with a 2-millimeter (mm) defect on the calvaria 





placed as a scaffold and various doses of AGF applied with or without different 
concentrations of HA (figure 3).  
 
 
Figure 4: Experimental Design. A. Dissected calvaria under sterile conditions. B. 
Cultured with bone formation medium on the metal mesh. C. 2.0mm critical defect was 
created by a tissue biopsy punch. D. Placement of calvaria on metal mesh. E. Scaffold 






 Figure 5: Tissue Engineering Triad for Experimental Design. This diagram 
demonstrates the three main components of the tissue engineering triad which include the 
cells, GFs, and scaffolds. 
 
Media Used for Cell and Organ Culture 
DMEM is unique as it contains 4 times the concentration of amino acids and vitamins as 
the original Eagle's Minimal Essential Medium. DMEM was originally formulated with 
low glucose (1 g/L) and sodium pyruvate but is often used with higher glucose levels 
4500 mg/L, with or without sodium pyruvate. DMEM contains no proteins, lipids, or 
growth factors. Therefore, DMEM requires supplementation, commonly with 10% 





and therefore requires a 5–10% CO2 environment to maintain physiological pH. This 
method was created by Dr. Erdjan Salih [43]. 
 
Bovine serum albumin (BSA) is a model protein in many studies. It is structurally well 
characterized, easily available in its native conformational state, useful in 
immunodiagnostic procedures, cell culture media and clinical chemistry, and relevant in 
foods containing bovine milk or meat. The primary structure of BSA was first reported in 
1971 and later revised in 1990 [44]. BSA contains 583 amino acids of which one Cys and 
seventeen (Cys)2 residues. 
 
L-ascorbic acid also known as Vitamin C is an antioxidant essential cofactor and for lysyl 
hydroxylase and prolyl hydroxylase, enzymes essential for collagen biosynthesis and 
regulation of development. Without ascorbic acid collagen synthesis would be deficient 
and abnormalities in collagen and bone formation would occur. Deficiencies in vitamin C 
can lead to conditions such as scurvy which causes gingiva bleeding, bone pain and 
impairs wound healing [45]. 
 
Statistical Analysis 
Alkaline phosphatase (ALP) activity is a marker for osteoblast activity and the enzyme 
activity is expressed in units of (nmol/L-1min-1/mg protein). Phosphatase substrate (PS) 
was added to ammonium bicarbonate to a final concentration of 10 mM. In a 96-wells 





37°C for 3 hours. Absorbance was set to 405 in the plate reader. The reagents used for 
ALP activity assay are as follows: 
1. Substrate: 0.67 mols (M) of phosphatase substrate  
i. To prepare: 123.5 mg of PS (sigma p4744 kept in -20 degree Celsius) 
mixed with 500 uL of distilled water in an Eppendorf  
2. Buffer solution: 2.0 mmol/L of MgCl2 with 0.1 mol/L of NaHCO3 at a pH of 9.8 
3. 0.67 M PS added into the buffer solution to make 6.7 mM PS 
i. 0.5 mL of 0.67M PS mixed with 49.5mL of buffer solution makes the final 
concentration of 6.7mM phosphatase substrate buffer 
4. Stop Solution: 0.2 N (mol/L) NaOH 
5. Standard Solution: 0.5 mmol/L p-nitrophenol  
i. Standard used: 0, 0.0625, 0.125, 0.25, 0.5, 1.0, 2.0 (mmol/L in distilled 
water) 
 
Each of the commonly used protein assay methods exhibit some degree of varying 
response toward different proteins. These differences relate to amino acid sequence, pI, 
structure, and the presence of certain side chains or prosthetic groups that can alter the 
protein’s color response. Most protein assay methods use BSA as a standard against 
which the concentration of protein in the sample is determined. However, if great 







After 35 days of culture, the calvaria were decalcified using the following decalcification 
buffer (2 liters): 280 grams EDTA (cat#: ED; Sigma), 1.5 liters of distilled water, 180 ml 
of ammonium hydroxide (cat#: 67-212; Fisher). The pH was adjusted to 7.1 with 
ammonium hydroxide.  
 
Hematoxylin and Eosin (H&E) 
The paraffin embedded tissue sections were stained with Hematoxylin and Eosin (H&E) 
and silver nitrate counter staining. For H&E staining, the calvaria sections were 
deparaffinized in the following solution: 
1. xylene for 10 minutes twice  
2. 100% ethanol for 10 minutes 
3. 95% ethanol for 10 minutes 
4. 90% ethanol for 10 minutes 
5. 70% ethanol for 10 minutes 
6. PBS solution. 
After deparaffinization, the staining was done as follows: 
1. Calvaria sections were kept in Hematoxylin for 5 minutes 
2. Washed in distilled water continuously for 5 minutes 
3.  5 dips of Eosin applied 
4. 10 dips of 95% ethanol twice 
5. 10 dips of 100% ethanol twice 





Finally, Cytoseal 60 was added followed by a cover slip and left to dry in the chemical 
hood overnight.  
 
Silver Nitrate Counter Staining 
Some samples were stained with silver nitrate counter staining using NovaUltra Special 
Stain Kits. This technique is to visualize deposits of calcium or calcium salts. Calvaria 
were treated with silver nitrate. The silver replaces the calcium and reduced by strong 
light seen as metallic silver. The following was used: 1% aqueous silver nitrate solution 
(silver nitrate 1 gram and distilled water 100ml) and 5% sodium thiosulfate (sodium 
thiosulfate 5 grams and distilled water 100 ml). The calvaria was washed with distilled 
water first and then incubated with 1% silver nitrate for 20 minutes under ultraviolet 
(UV) light. Then it was rinsed multiple times with distilled water. The unreacted silver 
was removed with 5% sodium thiosulfate for 5 minutes and again rinsed with distilled 
water. The UV light gives stronger reaction, so the calcium salts are often stained black.  
 





Masson Trichrome Staining 
Masson Trichrome stain is used to depict the histology of collagen, collagen fibers, fibrin, 
muscles, and erythrocytes. This stain used three stains, giving its name trichrome. These 
stains include: Weigert’s Hematoxylin, Biebrich scarlet-acid fuschin solution, and 
Aniline Blue.  
 
Reagents for Masson Trichrome Staining: 
Bouin’s Solution (It improves the quality of Masson Trichrome Stain) 
Saturated Picric acid ……………………………………………………….. 75 ml 
40% Formaldehyde………………………………………………………… 25 ml 
Glacial acetic acid……………………..…………………………………… 5 ml 
 
Weigert’s Iron Hematoxylin Solution 
Mix 1 volume of solution A with 1 volume of solution B 
 
Biebrich Scarlet-Acid Fuschin Solution 
1% aqueous Biebrich Scarlet……………………………………………….. 90ml 
1% aqueous Acid fuschin………………………………………………….. 10 ml 
Glacial acetic acid…………………………………………………………. 1 ml 
 
Phosphomolybdic-Phosphotungstic Acid Solution (P/P Acid) 





5% Phosphotungstic acid…………………………………………………… 25ml 
 
Aniline Blue Solution 
Aniline blue…………………………………………………………………… 2.5g 
Glacial acetic acid…………………………………………………………….. 2ml 
Distilled water……………………………………………………………… 100ml 
 
1% Acetic Acid Solution 
Glacial acetic acid…………………………………………………………… 1ml 
Distilled water……………………………………………………………….. 99ml 
 
For Masson Trichrome staining, the calvaria sections were deparaffinized in the 
following solution: 
1. xylene for 10 minutes twice  
2. 100% ethanol for 10 minutes 
3. 95% ethanol for 10 minutes 
4. 90% ethanol for 10 minutes 
5. 70% ethanol for 10 minutes 
6. PBS solution. 
After deparaffinization, the staining was done as follows: 
1. BOUIN’s solution for 15-30 minutes at 50 degrees Celsius (preheated) 





3. Run under tap water to remove yellow color for 17 minutes 
4. Add hematoxylin stain for 5 minutes 
5. Run under tap water for 10 minutes 
6. Rinse with distilled water  
7. Stain with Scarlet Acid Fusin for 10 minutes 
8. Rinse with distilled water 
9. Differentiate in P/P acid for 10-15 minutes until collagen loses its red color 
10. Stain with Aniline Blue for 5 minutes (do not wash in between step 9 and 10) 
11. Differentiate with 1% acetic acid 
12. Rinse in distilled water 
Dehydrate: 
1. 95% ethanol for 3 minutes 
2. 100% ethanol for 3 minutes 
3. Dehydrate in xylene and mount  
 
Staining Interpretation: Collagen fiber will stain blue, nuclei will stain black, and the 
background can stain red. Muscles, cytoplasm, and keratin stain red.  
 
 
Toluidine Blue Staining 
Toluidine Blue stain was discovered by William Henry Perkin in 1856 [46]. This stain is 






Reagents for Toluidine Blue staining: 
0.1M Acetate Buffer 
Anhydrous sodium acetate……………………………………………13.6g 
Distilled water………………………………………………………….900mL 




Sodium acetate buffer………………………………………………..100mL (0.1M) 
*Note: pH: 3.75-4.25 
 
For Toluidine Blue staining, the calvaria sections were deparaffinized in the following 
solution: 
7. xylene for 10 minutes twice  
8. 100% ethanol for 10 minutes 
9. 95% ethanol for 10 minutes 
10. 90% ethanol for 10 minutes 
11. 70% ethanol for 10 minutes 
12. Washed distilled water for 3 minutes twice 
After deparaffinization, the staining was done as follows: 





5. Wash with distilled water for 5 minutes twice 
6. Keep in Fast Green/Fast Red for 3-5 minutes 
7. Wash with distilled water for 5 minutes twice 
8. 95% ethanol for 3 minutes 
9. 100% ethanol for 3 minutes 
10. Dehydrate in xylene and mount  
 
Staining Interpretation: nuclei will stain red, and proteoglycans will stain purple. 
 
Picrosirius Red (PSR) Staining 
Picrosirius red staining was developed by Junqueira in 1979 and is an important stain to 
evaluate collagen networks in different tissues [47]. Picrosirius red staining is used to 
depict the histology of collagen fibers i.e., types I and III in paraffin-embedded tissue 
sections. PSR stain uses standard light microscopy and polarized light microscopy to 
distinguish between type I and III collagen fibers.  
 
Reagents for PSR staining: 
Picrosirius Red Solution 
Sirius red F3B (C.I. 35782) …………………………………………0.5grams 






Sirius red is available from Sigma-Alrich as “Direct Red 80” (Cat#365548). Saturated 








For PSR staining, the calvaria sections were deparaffinized in the following solution: 
1. xylene for 10 minutes twice  
2. 100% ethanol for 10 minutes 
3. 95% ethanol for 10 minutes 
4. 90% ethanol for 10 minutes 
5. 70% ethanol for 10 minutes 
After deparaffinization, the staining was done as follows: 
1. Stain nuclei with Weigert’s hematoxylin for 8 minutes 
2. Wash the slides for 10 minutes in running tap water 
3. Stain in picrosirius red for one hour  
4. Wash in two changes of acidified water 
5. Vigorously shake the slide to remove access water 





7. Dehydrate in xylene and mount  
 
Staining Interpretation: 
Under standard light microscopy, collagen will be red, muscles fiber will stain yellow, 
and cytoplasm will stain yellow. 
 
Under polarized light microscopy, type I collagen (thick fibers) will stain yellow or 
orange while type III collagen (thin fibers) will stain green. These are easily 




Figure 7: HA Concentrations. Experiment I Hyaluronic Acid Concentrations used; same 
concentrations were used in Experiment II with different groups. 
 
In this study, two experiments were performed. Each group consisted of a different 
biomaterial. Experiment I and II compared the following: 





a. Half Dose (5ul) 
b. Full Dose (10ul) 
ii. Concentrations of HA: 
a. 0% HA 
b. 0.0625% HA 
c. 0.125% HA 
d. 0.25% HA 
Note: The difference between experiment I and II is that experiment I distinguishes 
between the number of applications (single or multiple 4x) needed whereas experiment II 
shows results based on the dose of AGF needed (half or full dose of AGF). The 
application method is also different in both experiments to test the best application 
method.  
 
Figure 8: Experimental Design. This diagram represents the application of the GFs 






Experiment I: Single Application vs Multiple Applications (4x) of AGF  
Experiment I was divided into 8 groups i.e. A-H where the number of doses varied but 
the amount applied each was 5 ul. The controls for this groups were group A and group 
B, consisting of a 2mm defect with placement of a type I collagen membrane and a single 
dose (half-dose i.e., 5ul) of AGF. With no HA in this group and group B consisting of a 




 Experiment I was applied with type I collagen membrane and a single application a 
mixture of half dose of AGF with or without HA. The application of AGF was with a 
concentration of 5ul.  
 
Multiple Applications:  
In experiment I, the multiple applications were as follows: was applied with type I 
collagen membrane and a mixture of half doses of AGF with or without HA multiple 




Experiment II was divided into 12 groups which included multiple controls (figure 6).  





(i) Half Dose (5ul): placement of type I collagen membrane with a single 
application of AGF followed a concentration of HA with 5ul of DMEM 
(groups 1-4 only had AGF) after five minutes.  
(ii) Full Dose (10ul): placement of type I collagen membrane with a single 
application of 5ul of AGF followed by a mixture of 5ul of AGF and a 
concentration of HA after 5 minutes.  
 
The controls (single applications) included in experiment II: 
i. Defect with only type I collagen membrane + DMEM 







Figure 9: Experiment I Design. Each group consisted of calvaria with a 2mm defect 
covered with a type I collagen membrane plus the designated treatments.  
Calvaria were harvested under sterile conditions and 2 mm defect created by biopsy 
punch, and non-crosslinked type I collagen membrane were implanted as a scaffold for 
either Amniotic Growth Factors. Calvaria were cultured with DMEM + Ascorbic Acid 
(1mM) as a bone formation system for 28 days. Culture medium changed every other day 
Medias were collected: Day 1, Day 3, Day 5, Day 7…Day 35 for Alkaline Phosphatase 






Figure 10: Experiment II Design. Each group consisted of calvaria with a 2mm defect 
covered with a type I collagen membrane plus the designated treatments.  
Calvaria were harvested under sterile conditions and 2 mm defect created by biopsy 
punch, and non-crosslinked type I collagen membrane were implanted as a scaffold for 
either Amniotic Growth Factors. Calvaria were cultured with DMEM + Ascorbic Acid 
(1mM) as a bone formation system for 28 days. Culture medium changed every other day 
Medias were collected: Day 1, Day 3, Day 5, Day 7…Day 25 for Alkaline Phosphatase 








Figure 11: Calvaria Anatomical Definition. This figure refers to the breakdown of the 
areas of the calvaria. It is key to remember that the endocranium layer is closest to the 
titanium mesh and the bone culture media. The pericranium layer is where most of the 
application of treatments have been placed.  
 









Figure 13: Single Application with and without HA. Figure 13A shows two calvaria 
with different treatments on day 0. The calvarium on the left side in figure 13A shows 
placement of type I collagen with a single application of AGF only. The calvarium on the 
right side in figure 13A shows the placement of type I collagen with a mixture of AGF 
and 0.25% of HA. Figure 13B represents the clinical progress of the calvaria treatments 





seen especially towards the margins of the defect area. These figures represent 5ul of 
AGF with or without the HA. 
 
Figure 13A and 13B compare the applications at different day timepoints. Figure 13A 
compares day 0 application with the highest dose of HA concentration used in this 
experiment (0.25%) to that of no HA application (0%). Figure 13B compares day 21 
applications to see the bone formation over a period of 21 days. Clinically, it can be seen 
on day 21 that the margins of the defect area with the HA (0.25%) shows more bone 
formation as compared to the counterpart i.e., single dose of AGF only. It can also be 
noted that figure 13B shows a more seamless healing between the defect margin and the 








Figure 15 shows a comparison of multiple application of AGF (4x) to that of the AGF 
with 0.25% HA (4 times applications). Day 9 represents the day after the application of 
the last treatments (4th). Clinical pictures for day 21 suggest that the bone formation seen 
in AGF only treatments versus the AGF and HA treatments are different. On day 21, 
AGF with HA calvaria shows a much more conducive new bone formation that is not 
protruding out of the defect area as seen in the AGF only calvaria. AGF with HA on day 
21 also shows a more seamless healing between the defect margin and the non-affected 
calvaria. Please note that the concentration of HA in this figure is the highest 






Figure 16: Single Application (1x) vs. Multiple Applications (4x) on Day 21.  Figure 
16A shows the single application of treatments and figure 16B shows the multiple 
applications of treatments on calvaria by day 21. Figure 15A compares the AGF only 
treated calvaria to that of AGF and HA (0.125%) treated calvaria. The black arrow in 
16A shows a more prominent bone formation around the defect margin as well as some 
mineralization towards the center of the scaffold. This is not as prominent in the AGF 
treated only calvaria. The black arrow in figure 16B shows, not only a seamless healing 
around the defect margin, but also shows formation of bone towards the center of the 
scaffold. There is a far more unified and seamless around the HA treated calvaria, which 
is not seen in either of the non-HA treated calvaria. These figures represent 5ul of AGF 
with or without the HA. 
 
The comparison in figure 16 is between the number of applications, where figure 16A 
shows a single application with or without HA and figure 16B shows multiple 
applications with or with HA (all calvaria containing AGF). When comparing the day 21 
AGF only samples, the multiple applications of AGF seems to have a far better effect on 
the bone healing process. However, the healing is expanded beyond the defect area as 
seen clearly in figure 16B of the AGF only calvaria. If the day 21 AGF with HA treated 
calvaria were looked at, then it can be noted both single application and multiple 
applications show a seamless healing around the margins of the defect as well as bone 
mineralization towards the center of the defect area. This central mineralization is even 





healing stayed more so within the confine of the defect with HA treatments than that of 




Figure 17: Single Application (1x) vs. Multiple Applications (4x) on Day 21. Figure 
17A shows the single application of treatments and figure 17B shows the multiple 
applications of treatments on calvaria by day 21. Figure 17A shows compares the AGF 
only treated calvaria to that of AGF and HA (0.0625%) treated calvaria. The black 





little mineralization towards the center of the defect. Although the circumference of the 
defect has some bone formation it is not as prominent in the AGF treated only calvaria. 
Almost no mineralization of bone can be seen in towards the center of the defect in the 
AGF only treated. The black arrow in figure 17B shows, not only a seamless healing 
around the defect margin, but also shows formation of bone towards the center of the 
scaffold. There is a far more unified and seamless around the HA treated calvaria, which 
is not seen in either of the non-HA treated calvaria. However, it can be noted that in the 
multiplication applications of AGF only there is a protrusion of bone growth that is seen 
bulging out of the defect area, almost like an overgrowth, which is not seen as much with 







Figure 18: Single Application (1x) treatments on Day 35. This figure compares the 
results of all the treatments day 35 with just a single application. The black arrow in 
figure 18D shows that there is seamless healing between the affected and unaffected 
portions of the calvaria reaching the center of the scaffold. These figures represent 5ul of 
AGF with or without the HA. 
 
The purpose of this figure is to compare the AGF only treatment to the rest of the 
treatments of all HA concentrations used. In comparison to figure 18A, the other groups 
show promising bone healing. Figure 18A shows some bone healing around the periphery 





Figure 18B represents the lowest concentration of HA used in this experiment. In 18B 
there is seamless healing between the defect margin and the unaffected portion of the 
calvaria with mineralization towards the center of the defect. Figure 18C shows far better 
healing around the periphery of the defect, but also towards the center of the scaffold. 
There is a more unified bone formation around the defect area. Figure 18D shows the 
highest concentration of HA used in this experiment i.e., 0.25%. It can be noted that the 
clinical picture in figure 18D shows almost complete bone healing of the defect area. In 
comparison to figure 18A, figure 18D shows more mineralization in the defect area and a 
seamless healing between the margins of the defect and the unaffected area.  





results of all the treatments day 35 with multiple applications. The black arrow in figure 
18D that the margins of the defect are unidentifiable because of the seamless bone 
formation. These figures represent 5ul of AGF with or without the HA. 
 
Figure 19 represents the new bone formation seen among the different treatments. 
Although all figure 18A-D all show seamless healing at the defect margin, the main 
notation here is the volume of mineralization seen towards the center of the defect. In 
comparison to figure 19D, figure 19A shows less mineralization at the center of the 
defect. If figures 18 and 19 were compared, then figure 18B and figure 19A show similar 
results. Therefore, according to the clinical pictures, it can be suggested that a single dose 
of AGF with HA shows similar results to that of multiple applications of AGF only. It 
can also be noted that HA treated calvaria show far more seamless healing in and around 







Figure 21 shows the single application of treatments with 10ul of AGF with or without 
HA. These applications are like experiment I, however the application method was 
different in experiment II. In figure 21, full dose of AGF (5ul) was applied either with or 
without HA and five minutes after 5ul of DMEM was applied. Figure 21A shows a slight 
discontinuity between the defect margin and the scaffold which is not seen in figures 
21B-D. Figure 21B shows a seamless bone formation around the periphery of the defect 
margin with mineralization towards the center of the scaffold. Figure 21D shows 
continuous new bone formation around the defect area and into the center of the scaffold. 
Figure 22: H&E Staining of Group A, Experiment I. This figure represents the right 





only. The yellow box represents a far less organized collagen matrix. The dotted line seen 
on the clinical photo of the calvaria represents where the sectioning was made. 
 
In experiment I, all treatments were applied using 5ul of AGF for each application. The 
concentration of HA varied from 0% HA to 0.25% HA depending on the experimental 
group. In figure 22, the pericranium side of the stain shows far more activity as compared 
to the endocranium side. However, the endocranium side shows has more organized 
formation of bone with layers of fibroblasts as this side was closer to the bone culture 
media (liquid). What appears to be chondrocytes are seen more so in the scaffold area 
towards the endocranium side. Although some cellular activity is seen towards the 
unaffected area of the pericranium side, little cellular migration seen in the scaffold area. 






Figure 23: H&E Staining of Group C, Experiment I. This figure represents the right 
side of the defect area and the activity of a single, half dose (5ul) application of AGF with 
0.0625% HA. The yellow box shows that there is some cellular migration seen towards 
the center of the defect area. The dotted line seen on the clinical photo of the calvaria 
represents where the sectioning was made. 
 
In figure 23 shows the application of a single, half dose (5ul) of AGF with the lowest 
concentration of HA used in this experiment i.e., 0.0625% HA. If compared to figure 22, 
there is far more cellular migration is seen towards the center of the scaffold. It can also 





suggesting more hyaline cartilage formation. There is also far cellular engagement seen 
on the pericranium side in figure 23 in comparison to figure 22.  
 
 
Figure 24: H&E Staining of Group C, Experiment I. This figure represents the left side 
of the defect area and the activity due to multiple application of AGF only. The yellow 
box represents the activity from the defect margin into the scaffold area. The dotted line 






In experiment I, all treatments were applied using 5ul of AGF for each application. The 
concentration of HA varied from 0% HA to 0.25% HA depending on the experimental 
group. In figure 24, the pericranium side of the stain shows far more activity as compared 
to the endocranium side. However, the endocranium side shows far more organized 
formation of bone with layers of fibroblasts as this side was closer to the bone culture 
media (liquid). The pericranium side shows more activity due to the applications of the 
treatment. More organized osteoid formation is seen below the original bone area, 
however, there is some osteoid formation seen above the original bone along with 
osteoblastic activity. In comparison to figure 22, there is evidently more cellular 
migration into the scaffold area seen along the defect margin. The collagen scaffold is 
showing more organization than that of figure 22. However, it is also important to note 
that figure 22 represents a single, half dose (5ul) of AGF alone whereas figure 24 shows 





Figure 25: H&E Staining of Group G, Experiment I. This figure represents the left side 
of the defect area and the activity of multiple (4x), half dose (5ul) application of AGF 
with 0.0625% HA. The yellow box shows that there is some cellular migration seen 
towards the center of the defect area. The dotted line seen on the clinical photo of the 
calvaria represents where the sectioning was made. 
  
Figure 25 represents the lowest concentration of HA used in this experiment i.e., 
0.0625%. Although figure 25 shows treatment with 4x AGF and 0.0625% HA, the 
cellular migration into the defect area is like that of figure 23. The pericranium side 





fibroblast layers. Between the collagen matrix, there are chondrocytes seen as well as 
some cartilage formation. There are some osteoclasts seen closer to the original bone area 
and osteoblast and bone lining cells are seen at the pericranium end. However, there is 
less cellular proliferation towards the center of scaffold as compared to figure 24, but far 
more than figure 22. 
 
Figure 26: H&E Staining of Group D, Experiment I. This figure represents the right 
side of the defect area and the activity of a single, half dose (5ul) application of AGF with 





center of the defect area as well as cartilage formation. The dotted line seen on the 
clinical photo of the calvaria represents where the sectioning was made. 
 
In figure 26, cellular infiltration is seen throughout the defect area and there seems to be 
cartilage laid down between the thicker collagen matrices. It is quite apparent that the 
collagen matrix is much thicker in this figure as compared to figures 22-25. The hyaline 
cartilage seen here is much evident than in figure 24. The new osteoid formation below 
the original bone towards the endocranium area is much more organized with layers of 
fibroblasts. The scaffold area shows organized formation.   
Figure 27: H&E Staining of Group H, Experiment I. This figure represents the left side 
of the defect area and the activity of multiple (4x), half dose (5ul) application of AGF 





towards the center of the defect area along with cartilage formation. The dotted line seen 
on the clinical photo of the calvaria represents where the sectioning was made. 
 
 In figure 27, defect area shows new bone formation with thicker collagen matrix. There 
is an enormous amount of cellular migration into and around the defect area with 
cartilage laid down. Below the original bone, new bone formation is seen towards the 
endocranium side with layers of fibroblast. Above the original bone, new bone formation 
is also seen, and it is much more organized as compared to groups A, B, C, D, and G. 
There is a lot of cellular proliferation seen at the pericranium side and especially at the 
defect area with evident hyaline cartilage. In between the collagen scaffold, there are 





Figure 28: H&E Staining of Group E, Experiment I. This figure represents the right 
side of the defect area and the activity of a single, half dose (5ul) application of AGF with 
0.25% HA. The yellow box shows that there is more cellular migration seen towards the 
pericranium portion of the defect as well as cartilage formation. The dotted line seen on 
the clinical photo of the calvaria represents where the sectioning was made. 
 
Figure 28 represents the highest concentration of HA used in this experiment i.e., 0.25%. 
In comparison to figure 27, this figure shows more cellular proliferation at the 
pericranium side of the defect. There are more chondrocytes seen at the pericranium side 





pericranium side. Although the new osteoid is not as clear in figure 28 in comparison the 
other groups, there are chondrocytes seen above the original bone area suggesting 
potential hyaline cartilage formation. There is also less new bone formation seen below 
the original bone towards the endocranium side in comparison to the other groups, 
although fibroblasts layers are seen.  
 
 
Figure 29: H&E Staining of Group F, Experiment I. This figure represents the left side 
of the defect area and the activity of multiple (4x), half dose (5ul) application of AGF 
with 0.25% HA. The yellow box shows that there is more organized cellular migration 





margin and towards the original bone. The dotted line seen on the clinical photo of the 
calvaria represents where the sectioning was made. 
 
 In figure 29, far more cellular infiltration is seen leading towards the defect area. 
Collagen matrix is covering the micro-gaps that is like Group B (no HA). However, the 
cellular proliferation is far more organized in this figure than in group B. The new bone 
formation is much more organized between the original bone. The cellular migration is 
seen towards the scaffold towards the endocranium side as well. It is also evident that the 
cellular migration into the defect area is distributed throughout the scaffold (between the 










Figure 30: H&E Staining comparing groups 11 and 12, experiment II. These figures 
compare the effects of collagen type I scaffold to that of collagen type I scaffold with the 
application of a mixture of 0.25% HA with DMEM.  The figure on the left represents type 
I collagen and the figure on the right represents type I collagen with the mixture of HA 
and DMEM. The yellow boxes refer to the effects seen towards the center of the scaffold. 
The red box represents new bone formation towards the endocranium side.  
 
Figure 30 can be used as a baseline or control as to which the other groups can compare 
to. Group 11 as seen on the left side shows formation of the collagen matrix in the 
scaffold area. There is no cellular proliferation in the stain on the left. Also, there is 
almost no cartilage formation seen on the figure on the left. There is some new bone 
formation seen below the original bone towards the endocranium side which can be due 
to the bone media (liquid) that calvaria on the mesh was placed on. There is minimal new 
bone formation above the original bone towards the pericranium side, although some 





0.25% HA application. In comparison to the image on the left, the image on the right 
shows more cellular activity between the areas of the original bone along with layers of 
fibroblast towards the endocranium side. The defect area in the image to the right shows 
that there is some cellular activity along with cartilage formation along with a more 
profound collagen matrix. The collage and cartilage formation are extending into the 
margins of the defect in the image on the right.  
 
One of the main differences between experiment I and II are the method of applications. 
Experiment I was designed to understand the differences among each group based on the 
number of applications of treatments i.e., single applications vs. multiple applications. 
Experiment II was designed to primarily test the differences between the dose of AGF 
applied i.e., half dose (5ul) or full dose (10ul).  
 
Another important notation is that both experiments had a different method of 
application. Experiment I’s application method was as follows: (i) placement of type I 
collagen membrane into the defect area and (ii) application of treatment (AGF only or 
mixture of AGF with HA). Experiment II’s application method was divided into two 
ways based on odd or even groups (groups 1-10).  The odd groups’ application method 
was as follows: (i) placement of type I collage membrane, (ii) first application of 
treatment, (iii) wait for five minutes, (iii) second application of treatment. It is important 
to note that only two groups in experiment II were treated with multiple application 







Figure 31: H&E Staining comparing experiment I groups A and B with experiment II 
groups 3 and 4 single vs multiple applications of half doses of AGF (5ul). 
 
The main purpose of figure 31 is to compare the differences between the two experiments 
done when looking at the effects of AGF only. Group A was applied with type I collagen 
membrane and a single application of half dose of AGF whereas group B was applied 
with type I collagen membrane and multiple (4x) applications of half doses of AGF. 
Group 3 and 4 were part of the second experiment where group 3 included type I collagen 





and group 4 included type I collagen membrane with multiple (4x of 5ul) application of 
AGF each time followed by 5ul of DMEM after five minutes. Each group shows a vastly 
different histological picture. Although the only difference between group A and group 3 
is the application method, group A shows far more collagen matrix structure. Group 3 has 
a significant micro-gap that is seen not only in the stain, but also in the clinical picture. 
Group A shows far more cellular infiltration notably in the direction of the endocranium 
aspect of the scaffold area in comparison to group 3, which may be due to the micro-gap. 
Group B and group 4 show some similar activities. Both groups here show cellular 
infiltration into the defect area as well as cartilage formation as well as new bone 
formation. This is not seen quite as much in group B or group 3. Although, in comparison 
to group B, group 4 shows many more layers of fibroblasts especially towards the 







Figure 33: H&E stains comparing experiment I groups with 0.0625% HA to 
experiment II groups with 0.0625% HA with single or multiple applications of half 
(5ul) or full (10ul) applications of AGF. 
 
The purpose of figure 33 is to compare the differences between the two experiments 
based on the effects of the lowest concentration of HA used in the two experiments i.e., 
0.0625%. Group C was applied with type I collagen membrane and a single application a 
mixture of half dose of AGF and 0.0625% HA whereas group G was applied with type I 
collagen membrane and a mixture of half doses of AGF with 0.0625% HA multiple times 
(4x) over a period of a week. Group 5 and 6 were part of the second experiment where 
group 5 included type I collagen membrane with a single application of AGF followed by 
0.0625% HA with 5ul of DMEM after five minutes. Group 6 included type I collagen 
membrane with a single application of 5ul of AGF followed by a mixture of 5ul of AGF 
and 0.0625% HA after 5 minutes. Groups 5 and 6 differ in the dosage of the treatments 
where one is half dose and other is full dose, respectively, whereas group C and G differ 
based on the number of applications of treatments.  Although group C and G show almost 
results, groups 5 and 6 are different from group C and G. Group 5 does not have similar 
cellular infiltration into the defect area as seen in groups C and G. The blue box depicts in 
group 6 shows that there is a lot of micro-gaps present between the scaffold suggesting 
that there was not much cellular infiltration into the scaffold area. Group 5 and 6 show 
new bone formation and cartilage formation near the pericranium area above and around 






The focus of figure 34 is to compare the differences between the two experiments based 
on the effects of the concentration of HA i.e., 0.125%. Group D was applied with type I 
collagen membrane and a single application a mixture of half dose of AGF and 0.125% 
HA whereas group H was applied with type I collagen membrane and a mixture of half 
doses of AGF with 0.125% HA multiple times (4x) over a period of a week. Group 7 and 
8 were part of the second experiment where group 7 included type I collagen membrane 
with a single application of AGF followed by 0.125% HA with 5ul of DMEM after five 
minutes. Group 8 included type I collagen membrane with a single application of 5ul of 
AGF followed by a mixture of 5ul of AGF and 0.125% HA after 5 minutes. Groups 7 and 
8 differ in the dosage of the treatments where one is half dose and other is full dose, 
respectively, while group D and H different based on the number of applications of 
treatments. Although group D and group 7 only differ in the application method, group 7 
illustrates far more bone and cartilage growth around the defect area and mainly towards 
the pericranium side of the defect. Group D shows far more new bone formation around 
the original bone area whereas that is not as significant in group 7. Group 7 shows far 
more cellular proliferation and cellular migration around the center of the defect as well 
as towards the endocranium side of the defect which is not as significant in group D. 
Group H and group 7 show comparable results in the sense that the cellular migration and 
proliferation into the scaffold is quite considerable. Although group 8 shows far more 
hyaline cartilage around the original bone area, there seems to not be much cellular 
migration into the scaffold area. There is some collagen matrix formation in group 8, but 






half dose of AGF and 0.25% HA whereas group F was applied with type I collagen 
membrane and a mixture of half doses of AGF with 0.25% HA multiple times (4x) over a 
period of a week. Group 9 and 10 are part of the second experiment where group 9 
included type I collagen membrane with a single application of AGF followed by 0.25% 
HA with 5ul of DMEM after five minutes. Group 10 included type I collagen membrane 
with a single application of 5ul of AGF followed by a mixture of 5ul of AGF and 0.25% 
HA after 5 minutes. Groups 9 and 10 differ in the dosage of the treatments where one is 
half dose and other is full dose, respectively, while group E and F different based on the 
number of applications of treatments. Although group E and group 9 only vary in the 
application method, group E shows far more cartilage formation into the defect area and 
particularly in the direction of the pericranium side of the defect. Group E and group 9 
both demonstrate less proliferation into the defect area towards the endocranium side of 
the section whereas group F shows far more activity towards the endocranium space. 
Group E and F show far more chondrocytes markedly in the direction of the pericranium 
side in comparison to group 9 and 10. Although there seems to be newer osteoid laid 
down around the original bone in group 9, there seems to be some chondrocyte activity 
below the original bone in group 10. Group 10 has a significant amount of hyaline 
cartilage formation towards the pericranium portion of the defect as well as more 
osteoclastic activity. The collagen matrix is far more significant in group 10 in 





Figure 36: H&E stains compared to Masson Trichrome stains for treatments with 
0.0625% HA between Experiment I and Experiment II. 
 
Figure 36 compares the H & E stain to that of Masson for each group in respects to the 
application of 0.0625% HA. Groups C and G compares the application of a single, half 
dose of AGF to that of multiple applications of half dose of AGF which was applied over 
a period of a week. Group C (figure 36B) suggests that there is a lot of collagen 
production especially towards the pericranium side. However, group G (36D) shows even 
more collagen production. Groups 5 and 6 are part of experiment II and the focus here is 
to differentiate between a single, half dose (5ul) application of AGF with 0.0625% HA to 
single, full dose (10ul) application of AGF with 0.0625% HA. In this figure, there is not a 






Figure 37: H&E stains compared to Masson Trichrome stains for treatments with 
0.125% HA. 
 
Figure 37 compares the H & E stain to that of Masson for each group in respects to the 
application of 0.125% HA. Groups D and H compares the application of a single, half 
dose of AGF to that of multiple applications of half dose of AGF which was applied over 
a period of a week. Group D (figure 37B) suggests that there is a lot of collagen 
production especially towards the pericranium side. However, group H (37D) shows even 
more collagen production. Groups 7 and 8 are part of experiment II and the focus here is 
to differentiate between a single, half dose (5ul) application of AGF with 0.125% HA to 
single, full dose (10ul) application of AGF with 0.125% HA. In this figure, there is a 
difference between figures 37F and 37G especially towards the defect scaffold area 







Figure 38: H&E stains compared to Masson Trichrome stains for treatments with 
0.25% HA. 
 
Figure 38 compares the H & E stain to that of Masson for each group in respects to the 
application of 0.25% HA. Groups E and F compares the application of a single, half dose 
of AGF to that of multiple applications of half dose of AGF which was applied over a 
period of a week. Group E (figure 38B) suggests that there is a lot of collagen production 
especially towards the pericranium side and cellular activity is seen within the scaffold 
area. However, group H (37D) shows even more collagen production and cellular activity 
towards the center of the scaffold. Groups 9 and 10 are part of experiment II and the 
focus here is to differentiate between a single, half dose (5ul) application of AGF with 
0.25% HA to single, full dose (10ul) application of AGF with 0.25% HA. In this figure, 
there is a difference between figures 38F and 38G especially towards the defect scaffold 




















Figure 40: H&E stains comparison between half dose and full dose applications of 
AGF from Experiment II. 
 
In figure 40, the comparison is between the treatments with half (5ul) dose of AGF versus 
full (10ul) of AGF. It is quite apparent in all the stains that the pericranium side has 
significantly more cellular activity in contrast to the endocranium side. It can also be 
noted the collagen matrix is denser towards the center and in the direction of the 
endocranium side of the defect. In the full dose of AGF with 0.125% HA and 0.25% HA 
there seems to be more hyaline cartilage production. In the half dose of AGF with 
0.125% HA, there seems to be more intricate cellular migration and proliferation into the 
defect area with a lot of cartilage and collagen being laid down. The collage scaffold 
seems to be intertwined into between the defect area and the unaffected area. Full dose of 
AGF with 0.0625% HA shows more cellular proliferation at the pericranium side in 
contrast to the half dose of HA with 0.0625% HA. It also seems like the cellular 
migration infiltrated into the center portion of the scaffold in the full dose of AGF with 





Figure 41: H&E stains comparison between 1x AGF with HA vs. 4x AGF from 
Experiment I. 
 
Figure 41 aims to compare the differences concerning no HA application to the 
treatments with HA. This figure compares different concentrations of HA to that of AGF 
alone (0% HA). It is seen in treatments with HA shows results like 4x AGF. According to 
this figure, 0.125% shows findings that are the most like of 4x AGF with far more 
collagen matrix. It can also be noted that 1x AGF with 0.125% shows a more structured 
matrix where as in 4x AGF is the matrix seems to be considerably more expanded. 






In figure 42, the blue stain represents collagen formation in the groups. An important note 
to make here is that this figure compares the 4x AGF applications to that of 1x AGF with 
different treatments of HA. This is an important comparison to see the effects of HA and 
to see whether it a single dose of AGF with HA treatments can compare to multiple doses 
of just HA. Although 4x of AGF shows promising collagen formation, concentrations of 
0.0625% and 0.125% of HA with 1x AGF also show collagen formation that are 
comparable to 4x AGF. It can also be seen those treatments with HA show more collagen 
formation in the defect scaffold area in comparison to just 4x AGF which could possible 
mean that there is more proliferation of cells into the scaffold area with treatments of HA. 
The yellow box in each group represents an acellular space that is staining blue especially 
in between the collagen scaffold matrix. It may be plausible to say that is HA filling in 
between the collagen membrane matrix as HA is acellular and can be represented by the 
blue staining, which is not seen in the 4x AGF group only.  
Figure 43: H & E stains compared to toluidine blue stains among groups with 








experiment I. Groups F and G are multiple applications of treatments. All three groups 
represent AGF application with HA concentrations. Group E (figures 46A-C) signifies a 
single dose of AGF with 0.25% HA, which is the highest concentration of HA used in 
this experiment. It can be noted that figure 46B shows new bone formation by the 
representation of the blue staining that is especially observed in between what may be 
chondrocytes. The yellow boxes in figure 46F and 46I represent the filler space in 
between the collagen scaffold matrix. It may be plausible to say that is HA filling in 
between the collagen membrane matrix as HA is acellular and can be represented by the 
blue staining, which is not seen in the 4x AGF group only. 
Figure 47: Different stain comparisons for treatments with 0.0625% HA. 
 
In figure 47, groups C and G are part of experiment I and in this figure their comparison 
is to be made between 1x AGF with 0.0625% HA (group C) to that of 4x AGF with 





same section in different stains. Figure 47E represent the PSR staining in bright field that 
can be compared to light microscopy whereas figure 47F represents PSR staining in 
polarized light microscopy. Figures 47 C-D and G-H are of group G and are comparing 
the same section in different stains. Figure 47G represent the PSR staining in bright field 
that can be compared to light microscopy whereas figure 47H represents PSR staining in 
polarized light microscopy. Under the bright field, the collagen appears to be stained 
bright red. Under polarized microscopy, type I collagen is characterized by the 
yellow/orange staining and type III collagen is characterized by green staining. In 
comparison to figure 47F, figure 47H shows far more type I collagen especially around 
the original bone and towards the pericranium aspect while the endocranium aspect 
shows more type III collagen. It can also be noted that figure 47H shows far more type I 
collagen infiltrated into the defect area in comparison to that of 47F. In all the figures, the 
original bone can be appreciated, and comparisons can be made based on that.  
 





In figure 48, groups D and H are part of experiment I and in this figure their comparison 
is to be made between 1x AGF with 0.125% HA (group D) to that of 4x AGF with 
0.125%HA (group H). Figures 48 A-B and E-F are of group D and are comparing the 
same section in different stains. Figure 48E represent the PSR staining in bright field that 
can be compared to light microscopy whereas figure 48F represents PSR staining in 
polarized light microscopy. Figures 48 C-D and G-H are of group H and are comparing 
the same section in different stains. Figure 48G represent the PSR staining in bright field 
that can be compared to light microscopy whereas figure 48H represents PSR staining in 
polarized light microscopy. Under the bright field, the collagen appears to be stained 
bright red. Under polarized microscopy, type I collagen is characterized by the 
yellow/orange staining and type III collagen is characterized by green staining. In 
comparison to figure 48F, figure 48H shows far more type I collagen especially around 
the original bone and towards the pericranium aspect while the endocranium aspect 
shows more type III collagen. It can also be noted that figure 48H shows far more type I 
collagen infiltrated into the defect area in comparison to that of 48F. In all the figures, the 
original bone can be appreciated, and comparisons can be made based on that. In 
comparison to figure 47F, figure 48F shows more type I collagen as well type III collagen 
especially around the original bone. It can also be noted that figure 48F is like 47H which 
comparisons applications of 1x AGF with 0.125% HA to 4x AGF with 0.0625% HA 
respectively. However, in contrast to figure 47H, 48H shows more condensed collagen 







Figure 49: Different stain comparisons for treatments with 0.25% HA. 
In figure 49, groups E and F are part of experiment I and in this figure their comparison is 
to be made between 1x AGF with 0.25% HA (group E) to that of 4x AGF with 0.25%HA 
(group F). Figures 49 A-B and E-F are of group D and are comparing the same section in 
different stains. Figure 49E represent the PSR staining in bright field that can be 
compared to light microscopy whereas figure 49F represents PSR staining in polarized 
light microscopy. Figures 49 C-D and G-H are of group F and are comparing the same 
section in different stains. Figure 49G represent the PSR staining in bright field that can 
be compared to light microscopy whereas figure 49H represents PSR staining in 
polarized light microscopy. Under the bright field, the collagen appears to be stained 
bright red. Under polarized microscopy, type I collagen is characterized by the 
yellow/orange staining and type III collagen is characterized by green staining. 
In comparison to figure 49F, figure 49H shows far more type I collagen especially around 





shows more type III collagen. It can also be noted that figure 49H shows far more type I 
collagen infiltrated into the defect area in comparison to that of 49F. In all the figures, the 
original bone can be appreciated, and comparisons can be made based on that. Figures 
48H and 49H show comparable results.  
 
Figure 50: BCA Total Protein Analysis. This figure shows the difference in the protein 
levels tested on days 0, 3, 7, and 17. It compares the results of multiple applications of 
AGF (4x) without HA to those samples that were treated with only one application of 
AGF and various concentrations of HA. 
 
This BCA shows the total protein found on Day 0, 3, 7, 17. According to this data, it 
appears that there a significant increase in the total protein concentration in single dose of 
AGF with 0.125% HA on Day 7. The total protein concentration of multiple doses (4x) of 






Figure 51: ALP Analysis for single dose of AGF with HA to multiple doses of AGF 
without HA. This figure compares the results of multiple applications of AGF (4x) 
without HA to those samples that were treated with only one application of AGF and 
various concentrations of HA. 
 
According to the ALP activity, single dose of AGF with 0.25% is significantly increased 
on Day 3 and single dose of AGF with 0.125% is increased on Day 5. Multiple doses (4x) 
of AGF are increased much later as compared to the single dose of AGF suggesting that 






 Figure 52: Total ALP Analysis. This figure shows the activities of all the groups 




Bone is an active organ with anabolic and catabolic process. Under a normal ecosystem 
formation and resorption phases of bone are balanced. Bone healing is a complex process 
that involves molecular changes and bone matrix comprises of collagen proteins.  
The ability of bone to repair and regenerate after injury and to remodel is due to the bone 
formation by osteoblasts and bone resorption by osteoclasts leading to appropriate bone 





during normal bone growth as well as in conditions such as osteoporosis or fracture 
healing. 
 
The calvaria defect model is useful in the application of bone tissue regeneration. 
However, where there is critical defect in bone, the ability to form bone is affected by 
various conditions such as infection, inadequate stability, and improper vascularity. In 
1908, Lexer defined tissue engineering as a structural tissue in a use of freshly amputated 
or cadaver allografts for joint reconstruction. During that period, substituting limbs, teeth, 
and different tissues with synthetic or prosthetic substances resulted in partial recovery 
and some loss of function. These techniques, in the past, have caused contamination 
when placing the foreign material [2]. Tissue engineering is used to restore and 
regenerate biologic tissues through application and control of cells, materials, and the 
microenvironment into which these cells are delivered. Scaffolds are a critical part in 
providing the stability to the cells and the structures before new extracellular matrix 
synthesis occurs. It is usually appropriate to have scaffold that provide the same 
mechanical support to that of the tissue [2]. Latest materials are being constructed to play 
a more active role in tissue development so that the scaffold is not just holding cells in 
place but also encouraging bioactive matrices These scaffolds are being designed so that 
there may be better suited for cell attachment.  
 
Tissue engineering requires three factors: cells, a scaffold, and adequate nutrient supply. 





the scaffold. Two scaffolds, collagen and hyaluronic acid were tested along with amniotic 
growth factors to determine their ability to aid in the healing process of a critical defect. 
In this ex-vivo model the nutrition is received via a constant supply of experimental 
media which included DMEM, and vitamin C.  
 
Growth factors are linear organic polymer that consists of amino-acid residues that are 
bonded together in a chain and act by locally regulating the cellular activity. GFs function 
by binding to large, cell-surface transmembrane receptors on the target cell and what we 
see in figure 2 occurs. Growth factors are linear organic polymer that consists of amino-
acid residues that are bonded together in a chain and act by locally regulating the cellular 
activity. GFs function by binding to large, cell-surface transmembrane receptors on the 
target cell and what we see in figure 2 occurs. Bone matrix contains numerous growth 
factors, including BMPs, TGF-β, IGF, PDGF, and FGF. Osteoblastic culture models, in-
vivo experimental, and clinical models show that these growth factors impact cellular 
proliferation, differentiation, protein synthesis as well as chemotaxis. Because GFs play 
critical roles in fracture healing, these peptides have become an essential area of research 
to enhance fracture healing.  
 
Hyaluronic acid (HA) is a linear glycosaminoglycan. HA is biocompatible and 
biodegradable and has anti-inflammatory and bacteriostatic action. Additionally, HA has 
important tissue healing properties and promotes cell migration, adhesion, and 





medical field and recently studies have been done on its application in dentistry [48]. One 
clinical study suggested that HA may accelerate the clinical attachment level when 
applied as an accessary treatment material to treat infrabony periodontal defects [49]. In 
another study HA gel was applied to accelerate the healing in tooth sockets of rats [50].  
 
In this study, HA was used as an accessory scaffold along with a type I collagen 
membrane to see its effects on bone healing. It was seen that in both experiment I and II 
showed seamless healing, not only around the periphery of the defect area, but also 
between the defect scaffold in comparison to the treatments performed without the 
scaffold. Studies suggest that HA has an osteoinductive property that promotes and 
accelerated the bone healing process [51]. It is known that AGF, AminoSpark, stimulates 
bone formation, but due to its half-live and the fact that it can easily be degraded, an 
additional scaffold was needed. In the previous studies it was also seen that a single 
application of AGF was not sufficient for proper bone healing of the defect area. 
However, with the application of AGF with HA in this experiment, a single application of 
AGF with HA has shown bone healing almost equivalent to that of 4x of AGF alone as 
seen in the clinical pictures in figure 13 and the histological pictures in figure 41.  
 
An important finding from this experiment was that the treatments done with HA showed 
far more chondrocytes as well as cartilage formation in comparison to the treatments 
done without HA. HA concentration 0.125% showed some of the best results in terms of 





24 had 4x AGF applications with no HA and figure 26 had 1xA AGF with 0.125% HA, 
and in this figure 26 showed far more organized bone healing between the defect margins 
and the defect scaffold and what would appear as cartilage formation into the scaffold 
area. This formation is not seen as much in figure 24. Figure 27 could also be compared 
to figure 24 as figure 27 included 0.125% HA with 4x application of AGF. Even in figure 
27, there is far more organization seen in the scaffold area with cartilage formation into 
the defect area as well as towards the pericranium aspect of the defect which is not as 
evident in figure 24. In all the findings, large chondrocytes have been present, especially 
in those areas with HA. It has been suggested in other studies that HA has a stimulatory 
effect on the metabolism of chondrocytes [52]. The glycoprotein CD44 receptor on the 
chondrocyte has the capability of acting as a receptor of HA and thereby this receptor 
acts as a mediator for biochemical interactions between HA and chondrocytes [52]. 
 
Cartilage formation, especially hyaline cartilage, has been consistent with most of the 
findings with treatments of HA. In figure 22 with one application of AGF only, the 
histology showed that there was less cellular migration into the defect scaffold area and 
thereby creating micro-gaps around the defect area as well as between the defect area and 
the unaffected bone. Although some fibroblast activity is seen at the pericranium side of 
the defect, no new cartilage formation seen in figure 22 in comparison to the others 
suggesting that AGF on its own has a short life and can easily be degraded if not applied 
multiple times or paired with an accessory collagen. In comparison to figure 22, figure 23 





0.0625% HA. The application with a single half dose of AGF (5ul) with an application of 
HA (0.0625%) showed far more cellular infiltration into the defect scaffold especially 
around the pericranium side of the defect. Noticeable cartilage formation was seen at the 
pericranium side in the application of 0.0625% of HA (figure 23). The collagen scaffold 
with 0.0625% HA was not as expanded out of the defect area as seen in figure 22 
suggesting that HA has a holding capacity and the ability to keep the growth factors in 
the defect area. It is important to remember that the size of HA is a critical for its 
biological functions, where the high molecular size of HA cannot penetrate as well.  
 
In the application where AGF was applied four times over a period of a week, there was 
far more cellular migration into the scaffold area (figure 24) with similar cartilage layout 
at the pericranium area of the defect as seen in figure 23. Treatments with the application 
corresponding to figure 24 but with an addition of the lower concentration of HA 
(0.0625%) showed more cartilage production, not only at the pericranium aspect, but also 
within the defect scaffold region (figure 25). Figure 25 is group G that had application of 
AGF with HA (0.0625%) applied four times over a period of a week and although less 
cellular infiltration was seen into the scaffold area in comparison to figure 24, more 
cartilage production was noticed in between the defect areas. Group D, 1x AGF with 
0.125% HA, showed in figure 26 that the collagen scaffold was much thicker in 
comparison to 4x AGF only. Figure 26 also suggests that more hyaline cartilage 
formation is seen throughout the defect area as well around the original bone, which in 





that HA has a huge effect on chondrocytes and how they react which could be due to the 
receptor present on the chondrocytes as stated earlier. Based on this, it can be noted that 
HA is providing a framework that stimulates chondrocytes and interacting with the 
receptors on it to lay down more cartilage thereby stimulating new bone formation. The 
term chondro means cartilage, thus the ECM of cartilage is secreted by chondroblast and 
these chondroblast then secrete the matrix and fibers and become trapped inside it, 
maturing into cells called chondrocytes.  
 
It is important to emphasize on the actions of chondrocytes in this research. It can be 
understood that because neonatal mice were sacrificed during this experiment that the 
chondrocyte representation in many of the staining is expected. It is vital to understand 
that the in a human newborn, the skull has 6 fontanelles that close at different times [53]. 
Although the skull typically goes through intramembranous ossification, it is important to 
note that at the base of the skull there can be several synchondrosis which are formed via 
endochondral ossification [54]. These are a type of cartilaginous joint, and before 
adulthood, the cartilage is converted into bone and therefore synchondrosis is essential 
for skull growth [55]. Hence, this indicates that the cranial base is developed by 
endochondral ossification [54]. The development of the cranial bases starts with 
condensation of the mesenchymal cells that form the cartilage primordium [56]. The 
cranial base further elongates by the proliferation of chondrocytes preserving the 
synchondroses [54]. It is important to note that immature chondrocytes undergo 





perichondrium thereby creating ossification centers [54] [57].  It is important to note that 
mice undergo similar cranial formation as human neonates, however, an important 
distinction should be made between the calvarial sutures and cranial base synchondroses 
and facial sutures [58]. The calvarial sutures typically do not fuse in mice whereas the 
cranial base synchondroses and facial sutures do fuse [58].  
 
Another important finding in the treatments with HA are layers of fibroblast seen 
especially towards the endocranium area like in figure 34 and group G in figure 33. In an 
article written by Dr. Charles Vacanti, he mentioned that in a case of tissue engineering, 
there was noticeable fibroblast presentation naturally occurring on a collagen fiber 
scaffold [1]. This could potentially suggest that near the collagen scaffold placed here, 
there may be an increase of fibroblast for that reason. Fibroblast is a biological cell that 
secretes collagen proteins that make the structural framework for tissues and plays a role 
in healing wounds [59]. It is important to note that fibroblast need a stable collagen 
scaffold to bind to [60]. Even in a biomimetic ECM, HA plays a big role where it has 
been suggested that HA interacts with cellular surface marker CD44 to influence the 
wound healing giving HA osteogenic effects. In a past paper, it was suggested that HA 
from the ECM can be integrated into the cytoplasm of osteoprogenitor cells and 
hydrolyzed through the CD44 interactions leading to ossification of bone, mostly by the 
endochondral process [61]. CD44 is a type I transmembrane glycoprotein [62]. In a study 
where NASHA Restylane was injected into damaged skin of the arm, it was found that 





of the fibroblast hence producing type I collagen [60]. It is important to note that NASHA 
Restylane is a product that is hyaluronic acid gel that is used as a dermal filler. Therefore, 
it is important to note that HA provides a framework for blood vessel formation as well 
as fibroblast migration especially during tissue repair [30].  
 
Naturally, HA is also one of the main components of amniotic fluid (AF) [38], which is 
found in the AGF used in this experiment (AminoSpark) [37]. It has been suggested that 
fetal wound heals rapidly and do not form scars because of the rich nutrients found in AF 
such as GF and HA [63]. Consequently, it can be noted that some of the treatments with 
just AGF have some component of HA naturally and could lead to the filler space seen in 
most of the histological pictures. Therefore, it can be expected that incorporating HA as 
an accessory scaffold not only improves healing, but also helps to increase the bone 
formation rate because of its osteoinductive and osteoconductive properties. In a study, 
amniotic membrane (AM) was used in conjunction with HA to accelerate would healing 
on a single full thickness skin wound on mice [64]. In this, the histological results 
showed that the wounds treated with HA and AM had thicker regenerated skin with more 
blood vessels seen [64].  
 
In figures that compared the toluidine staining to H&E showed that there was presence of 
proteoglycans. It is important to understand that PGs and GAGs are part of the ECM and 
they are both important factors in bone healing as they also contribute to preserving the 





tissues. Consequently, PGs and GAGs are implicated with collagen fiber development. 
PGs are found in different areas, especially in the intracellular membrane. They can 
either be expressed on surfaces of cells or in the ECM in tissues while GAGs are made up 
of repeating disaccharide unites of hexosamine and hexuronic acid linear polymers that 
connect to the core protein to make PGs [65]. In figure 43, there is a comparison to see 
the if H&E staining versus toluidine blue staining, Figure 43B shows that PG, which is 
observed by the dark purple stains, clustered at the endocranium side of the defect 
especially towards the original bone. Figure 43D shows heavy presence of PG on the 
pericranium side and particularly at the defect margin. In figure 43D, PG is also seen in 
between the new bone and collagen that has been laid down. Figure 43F and 43H have 
some PG activity but it does not compare to that of the others. This could be due to the 
application methods as 43F and 43H are part of experiment II and 43B and 43D are part 
of experiment I. Figure 46 shows the similarities in the results among the different stains 
of H&E, toluidine blue, and Masson Trichrome. Figure 46C and 46D compare the 
presence of PG in 46C to presence of collagen in 46D and it is important to note that 
where the PG structures are found in toluidine blue, there is collagen being laid down in 
the surrounding area around the PG. This is especially observed in figures 46E and 46F 
and 46H and 46I. Here it is important to note that PG is important for solid or good bone 
mass as well as good remodeling of bone, therefore, these stains suggest that solid bone 







Cells, growth factors, and scaffolds are three essential factors for tissue engineering. 
GFs improve angiogenesis, cell proliferation, and extracellular matrix production with 
controlled and continuous exposure of an active form. Our previous studies suggested 
that the multiple applications of human amnion growth factors (AGF) into osseous defect 
can “mimic in-utero” growth. However, multiple applications are challenging in clinical 
use. To help decrease the number of applications needed, an additional carrier or scaffold 
would beneficial. 
 
HA was incorporated into this research design to improve bone healing as a carrier and 
gradually release the active form of AGF hence contributing as an extra scaffold that 
could cover the micro-gaps and enhancing the cellular migration thus improving the 
clinical outcome.  
 
Previous results indicate that multiple applications of AGF achieved better bone 
formation in comparison to single dose of AGF alone. However, with the use of HA as an 
extra scaffold and a carrier, a single dose of AGF can achieve similar bone formation to 
that of multiple applications of AGF. This suggests that in a clinical scenario the number 
of clinical applications needed can be reduced thus improving the clinical outcome. 
 
Single dose of AGF without HA shows some cellular migration into the scaffold area, but 





with 0.125% HA with a single dose of AGF shows far more cellular infiltration into the 
defect area and what could suggest filling in these the micro-gaps. Thus, a single dose of 
AGF with HA can improve bone formation sanctioning a seamless surface healing 
around the defect area.  
 
0.0625% HA with multiple doses of AGF shows some cellular migration into the scaffold 
area but does not entirely fill in the micro-gaps as seen in single dose of AGF with 
0.125% HA. This suggests that a higher concentration of HA would be better in 
combination with AGF. With 0.125% HA with 4x AGF, there is a lot more cellular 
infiltration and bridging of the micro-gaps, which was not seen with 0.0625%. To find 
the optimal dose of HA needed to cover these micro-gaps 0.25% HA was used with 4x 
AGF. This shows far more cellular infiltration and bridging of the micro-gaps suggesting 
that a higher concentration of HA would be beneficial with AGF.  
 
At this point in time, further studies need to be done to better understand the abilities of 
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